Considering the crosstalk between c-Met and the HER family receptors [18,19,20], along with its involvement in mediating resistance to anti-HER targeted therapies [18,19,20,21], for the first time this study primarily aimed to investigate the in vitro and in vivo effectiveness of the combined treatments of the c-Met inhibitor EVOO-derived phenolic lead OC with the targeted therapeutic anti-EGFR/HER2 drug LP against HER2-positive BC. This evidence concerns the gene ERBB2 and breast cancer.